Fly News Breaks for December 27, 2019
Dec 27, 2019 | 08:40 EDT
Lake Street analyst Thomas Flaten lowered his price target for Aquestive Therapeutics to $10 from $11 to reflect an increased number of shares following the company's recently completed an equity financing. The analyst, however, reiterates a Buy rating on the name. He believes Aquestive is "fundamentally in a sound place," having removed the "capital overhang" from the shares.
News For AQST From the Last 2 Days
There are no results for your query AQST